A detailed history of Allianz Asset Management Gmb H transactions in Exact Sciences Corp stock. As of the latest transaction made, Allianz Asset Management Gmb H holds 21,503 shares of EXAS stock, worth $1.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,503
Previous 11,847 81.51%
Holding current value
$1.25 Million
Previous $500,000 192.8%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$42.43 - $70.83 $409,704 - $683,934
9,656 Added 81.51%
21,503 $1.46 Million
Q2 2024

Aug 13, 2024

SELL
$41.33 - $74.26 $165,278 - $296,965
-3,999 Reduced 25.24%
11,847 $500,000
Q1 2024

May 13, 2024

SELL
$56.27 - $73.77 $248,657 - $325,989
-4,419 Reduced 21.81%
15,846 $1.09 Million
Q4 2023

Feb 12, 2024

BUY
$59.06 - $75.72 $294,473 - $377,539
4,986 Added 32.63%
20,265 $1.5 Million
Q3 2023

Nov 13, 2023

SELL
$65.94 - $99.04 $71,808 - $107,854
-1,089 Reduced 6.65%
15,279 $1.04 Million
Q2 2023

Aug 11, 2023

SELL
$62.68 - $95.05 $9.91 Million - $15 Million
-158,086 Reduced 90.62%
16,368 $1.54 Million
Q1 2023

May 11, 2023

BUY
$47.19 - $70.77 $58,609 - $87,896
1,242 Added 0.72%
174,454 $11.8 Million
Q4 2022

Feb 13, 2023

SELL
$30.35 - $53.15 $690,705 - $1.21 Million
-22,758 Reduced 11.61%
173,212 $8.58 Million
Q3 2022

Nov 08, 2022

BUY
$31.97 - $49.37 $207,645 - $320,658
6,495 Added 3.43%
195,970 $6.37 Million
Q2 2022

Aug 12, 2022

BUY
$35.61 - $76.23 $1.55 Million - $3.31 Million
43,423 Added 29.73%
189,475 $7.46 Million
Q1 2022

May 13, 2022

SELL
$57.56 - $82.54 $88,009 - $126,203
-1,529 Reduced 1.04%
146,052 $10.2 Million
Q4 2021

Feb 11, 2022

BUY
$72.5 - $100.68 $15,732 - $21,847
217 Added 0.15%
147,581 $11.5 Million
Q3 2021

Nov 10, 2021

BUY
$90.24 - $124.05 $4.49 Million - $6.18 Million
49,800 Added 51.04%
147,364 $14.1 Million
Q2 2021

Aug 16, 2021

SELL
$93.66 - $139.27 $153,696 - $228,542
-1,641 Reduced 1.65%
97,564 $12.1 Million
Q1 2021

May 13, 2021

BUY
$116.57 - $155.01 $8.41 Million - $11.2 Million
72,116 Added 266.22%
99,205 $13.1 Million
Q4 2020

Feb 16, 2021

BUY
$99.61 - $142.12 $555,325 - $792,319
5,575 Added 25.91%
27,089 $3.59 Million
Q3 2020

Nov 13, 2020

SELL
$72.92 - $102.01 $10.7 Million - $15 Million
-146,673 Reduced 87.21%
21,514 $2.19 Million
Q2 2020

Aug 14, 2020

SELL
$55.75 - $92.75 $5.64 Million - $9.38 Million
-101,149 Reduced 37.55%
168,187 $14.6 Million
Q1 2020

May 14, 2020

SELL
$37.9 - $104.44 $8.9 Million - $24.5 Million
-234,783 Reduced 46.57%
269,336 $15.6 Million
Q4 2019

Feb 13, 2020

BUY
$77.66 - $99.74 $34.9 Million - $44.8 Million
448,895 Added 812.86%
504,119 $46.6 Million
Q3 2019

Nov 13, 2019

SELL
$90.37 - $122.49 $5.03 Million - $6.81 Million
-55,605 Reduced 50.17%
55,224 $4.99 Million
Q2 2019

Aug 08, 2019

SELL
$89.51 - $118.04 $6.55 Million - $8.64 Million
-73,180 Reduced 39.77%
110,829 $13.1 Million
Q1 2019

May 13, 2019

SELL
$61.98 - $96.5 $2.24 Million - $3.49 Million
-36,188 Reduced 16.43%
184,009 $15.9 Million
Q4 2018

Feb 14, 2019

BUY
$56.04 - $82.66 $7.77 Million - $11.5 Million
138,597 Added 169.85%
220,197 $13.9 Million
Q3 2018

Nov 13, 2018

BUY
$48.29 - $80.6 $3.94 Million - $6.58 Million
81,600 New
81,600 $6.44 Million
Q2 2018

Aug 13, 2018

SELL
$37.84 - $69.96 $859,686 - $1.59 Million
-22,719 Closed
0 $0
Q1 2018

May 14, 2018

BUY
$39.82 - $57.53 $628,598 - $908,168
15,786 Added 227.69%
22,719 $917,000
Q4 2017

Feb 13, 2018

SELL
$46.49 - $60.51 $6.29 Million - $8.18 Million
-135,266 Reduced 95.12%
6,933 $364,000
Q3 2017

Nov 13, 2017

SELL
$37.05 - $47.12 $828,289 - $1.05 Million
-22,356 Reduced 13.59%
142,199 $6.7 Million
Q2 2017

Aug 14, 2017

BUY
N/A
101,215 Added 159.8%
164,555 $5.82 Million
Q1 2017

Apr 17, 2019

BUY
N/A
63,340
63,340 $1.5 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.3B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Allianz Asset Management Gmb H Portfolio

Follow Allianz Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Allianz Asset Management Gmb H with notifications on news.